California-based AI precision biotechnology company Neuron23 has raised USD 100 million in a Series C funding round led by SoftBank Vision Fund 2 with participation from existing investors WestLake Village BioPartners, Kleiner Parkins, and others. This brings the company’s total funds raised to USD 213.5 million.
The proceeds will be directed toward advancing the company’s lead programs, bolstering its clinical development team, and developing its precision immunology platform. The funds will also be used to fuel the research on its Parkinson’s drug candidate “NEU-723”—targeting a protein called leucine-rich repeat kinase 2 (LRRK2)—which is expected to enter clinical trials by the end of 2022.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.